Ретроспективный анализ эффективности химиотерапии при платинорезистентном и платинорефрактерном раке яичников
Покатаев Илья Анатольевич, Стенина Марина Борисовна, Л В Чития et al. · Вестник РОНЦ им. Н. Н. Блохина РАМН · 2009
Therapeutic options in platinum-resistant and platinum-refractory ovarian cancer are unclear. The purpose of this retrospective analysis was to assess response to and toxicity of several chemotherapy regimens in patients with platinum-resistant and platinum-refractory ovarian cancer. The analysis covered treatment outcomes in patients managed during 1995 through 2007 and receiving paclitaxel, pegylated liposomal doxorubicin, topotecan, altretamine, oral etoposide and various platinum-based combinations. Pegylated liposomal doxorubicin, oral etoposide and platinum-based combinations appeared to induce the highest response. The relatively high response to platinum derivatives shows that definition criteria for platinum-resistant ovarian tumors are not adequate.
Cited by 0 works.